Inhalable corticosteroids in long-term COPD treatment;Inhalierbare Kortikosteroide in der Langzeittherapie der COPD

Pneumologie

Volumn 54, Issue 6, 2000, Pages 256-262

  Gillissen, A ^a   Barczok, M ^b   Buhl, R ^b   Kardos, P ^b   Magnussen, H ^b   Matthys, H ^b   Rabe, K F ^b   Rothe, T ^b   Russi, E W ^b   Schauer, J ^b   Schmitz, M ^b   Vogelmeier, C ^b   Wettengel, R ^b   Worth, H ^b   Menz, G ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MULTICENTER STUDIES;

EID: 0033932959     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-3826     Document Type: Article

References (43)

1. 1 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S120
2. 2 Barnes P, Godfrey S. Chronic obstructive pulmonary disease. London: Martin Dunitz, 1997
3. 3 Petty TL, Weinmann GG. Building a national strategy for the prevention and management of and research in chronic obstructive pulmonary disease. JAMA 1997; 277: 246-253
4. 4 British Thoracic Society. Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52: S1-S28
5. 5 Fabbri LM, Caramori G, Beghe B, Papi A, Ciaccia A. Chronic obstructive pulmonary disease international guidelines. Curr Opin Pulm Med 1998; 4: 76-84
6. 6 Fletcher C, Peto R. The natural history of chronic airway obstruction. Br Med J 1977; 1: 1645-1648
7. 7 Jeffery PK. Morphology of the airway wall in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143: 1152-1158
8. 8 Jeffery PK. Comparative morphology of the airways in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 150: S6-S13
9. 9 Oxman A, Muir DCF, Shannon HS, Stock SR, Hnizdo E, Lange HJ. Occupational dust exposure and chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 38-48
10. 10 Senior RM, Shapiro D. Chronic obstructive pulmonary disease: epidemiology, pathophysiology, and pathogenesis. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR, Senior RM (Hrsg.). Fishman's pulmonary diseases and disorders. New York: McGraw-Hill, 1998: 659-681
11. 11 Canadian Thoracic Society Workshop Group. Guidelines for the assessment and management of chronic obstructive pulmonary disease. Can Med Assoc J 1992; 147: 420-428
12. 12 Schäfer H, Ewig S, Gillissen A. Therapie der schweren Exazerbation bei chronisch obstruktiver Lungenerkrankung (COPD). Intensivmed. 2000b, im Druck
13. 13 Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees J. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-1420
14. 14 Wettengel R, Böhning W, Cegla U, Criée C, Fichter J, Geisler L, Fabel H, Köhler D, Konietzko N, Lindemann H, Magnussen H, Matthys H, Meister R, Morr H, Nolte D, Petro W, Schultze-Werninghaus G, Sill V, Sybrecht GW, Wiesner B, Worth H. Empfehlungen der Deutschen Atemwegsliga zur Behandlung von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem. Med Klinik 1995; 90: 3-7
15. 15 Jackevicius C, Joyce DP, Kesten S, Chapman KR. Prehospitalization inhaled corticosteroid use in patients with COPD or asthma. Chest 1997; 111: 296-302
16. 16 Kardos P. Differentialdiagnose Asthma - COPD. Münch Med Wschr 2000, im Druck
17. 17 Lepage T, Bourcereau J, Terrioux P, Velicitat P, Roche N. Influence des résultats du test de réversibilité de l'obstruction bronchique sur la prise en charge de bronchopneumopathies chroniques obstructives (BPCO) en pratique pneumologique. Rev Mal Respir 2000; 17: S25
18. 18 Barnes JP. Inhaled Corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 342-344
19. 19 Calverley PMA. Inhaled Corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 341-344
20. 20 Gillissen A. Kortisontherapie bei chronisch-obstruktiver Bronchitis - Contra-Position. Dtsch Med Wschr 2000; 125: 222-223
21. 21 Schäfer H, Ewig S, Gillissen A. Therapeutische Optionen im Management der stabilen chronisch obstruktiven Lungenerkrankung (COPD). Dtsch Med Wschr 2000a, im Druck
22. 22 Vogelmeier C. Kortisontherapie bei chronisch-obstruktiver Bronchitis - Pro-Position. Dtsch Med Wschr 2000; 125: 220-221
23. 23 Vestbo J, Sørensen T, Langer P, Brix A, Torre A, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 355: 1819-1823
24. 24 Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-1953
25. 25 Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-780
26. 26 Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; The ISOLDE trial. BMJ 2000; 320: 1297-1303
27. 27 Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway Jr WA, Enright PL, Kanner RE, O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1539-1541
28. 28 Barnes PJ. New therapies for chronic obstructive pulmonary disease. Thorax 1998; 53: 137-147
29. 29 McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997; 111: 732-743
30. 30 Renkema TEJ, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996; 109: 1156-1162
31. 31 Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 477-482
32. 32 Cox G, Whitehead L, Dolovich M, Jordana M, Gauldie J, Newhouse MT. A randomized controlled trial on the effect of inhaled corticosteroids on airways inflammation in adult cigarette smokers. Chest 1999; 115: 1271-1277
33. 33 Fujimoto K, Kubo K, Yamamoto H, Yamaguchi S, Matsuzawa Y. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest 1999; 115: 697-702
34. 34 Confalonieri M, Mainardi E, Della Porta R, Bernorio S, Gandola L, Beghé B, Spanevello A. Inhaled corticosteroide reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 583-585
35. 35 Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-548
36. 36 Llewellyn-Jones CG, Harris TA, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153: 616-621
37. 37 Efthimiou J, Barnes PJ. Effect of inhaled corticosteroids on bones and growth. Eur Respir J 1998; 11: 707-709
38. 38 Coldstein MF, Fallon Jr JJ, Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest 1999; 116: 1733-1749
39. 39 Calverley PMA. Re-assessing the evidence about inhaled corticosteroids in chronic obstructive pulmonary disease. Thorax 1999; 54: 3-4
40. 40 Pizzichini E, Pizzichini MMM, Gibson P, Parameswaran K, Gleich GJ, Berman P, Dolovich J, Hargreave FE. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158: 1511-1517
41. 41 Dompeling E, van Schayck CP, van Grunsven PM, van Herwaarden CLA, Akkermans RP, Molema J, Folgering H, van Weel C. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. Ann Intern Med 1993; 118: 770-778
42. 42 Prescott E, Langer P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J 1999; 13: 1109-1114
43. 43 Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-1947